Monoclonal antibodies, or mAbs, now take longer to develop and get approval in the U.S. because of the complexity of disease targets and largely unmet need for life-threatening conditions, among other reasons, according to a report by Lisa Natanson, a Deloitte Recap analyst. Despite this scenario, mAb developers are likely to see continued growth given the drugs' higher success rates when it comes to clinical trials and approvals, compared with large- and small-molecule drugs, Natanson said.

Full Story:

Related Summaries